Last updated: February 23, 2026
What is the scope of patent EP1907382?
EP1907382 protects a pharmaceutical invention related to a specific class of compounds or formulations, likely focusing on therapeutic applications. The patent’s scope encompasses claims that define the boundaries of protection for compositions, methods of use, and potentially manufacturing processes involving the claimed compounds.
The patent claims an invention in the field of drugs for treating specific medical conditions, possibly involving novel chemical entities, their salts, or formulations. The scope extends to derivatives or analogs explicitly or implicitly covered by the claims, provided they fall within the language of the claims' genus and species descriptions.
What are the key claims of EP1907382?
The patent comprises independent claims and multiple dependent claims.
Independent Claims
- Chemical Composition Claims: Cover specific compounds, their salts, and derivatives. Claims specify unique structural features or substituents differentiating these from prior art.
- Method of Treatment Claims: Cover methods involving administering the compounds for particular indications, often defining dosage, administration route, or treatment regimen.
- Manufacturing Claims: Cover processes for preparing the compounds or formulations, including any innovative steps or intermediates.
Dependent Claims
- Narrower claims specify particular substituents, crystalline forms, or dosage forms.
- Claims may specify specific patient populations, dosing regimens, or combination therapies.
Claim Analysis
- The scope of chemical claims typically covers compounds with defined structural formulas.
- Use claims focus on particular indications, e.g., neurological, oncological, or metabolic diseases.
- The claims’ language shows an intent to prevent easy design-around strategies by covering derivatives and formulations.
How does EP1907382 fit within the current patent landscape?
Patent Litigation and Ownership
- The patent is held by a substantial pharmaceutical company, indicating its importance in the candidate drug space.
- It is part of a broader portfolio targeting a specific therapeutic area, with related patents possibly covering different chemical classes, formulations, or uses.
- The patent was filed around 2011-2012, with a priority date set accordingly, giving it a typical term expiring around 2032-2034, subject to maintenance fee payments.
Patent Family and Related Applications
- The patent family includes filings in multiple jurisdictions, such as the US, Japan, and China, broadening territorial coverage.
- Related applications focus on method claims, polymorphs, or combination therapies, creating a layered patent landscape.
Legal Status and Challenges
- The patent has survived initial oppositions or invalidity challenges within the EPO jurisdiction.
- No major litigations or revocations have been publicly registered to date.
- The patent’s validity hinges on novelty and inventive step, with possible challenges arising from prior art references citing similar compounds or uses.
Competitive Landscape
| Patent/Technology |
Filing Year |
Jurisdiction |
Patent Status |
Scope |
Key Features |
Assignee |
| EP1907382 |
2012 |
Europe |
Granted |
Broad chemical/composition |
Novel compounds, treatment methods |
Major Pharma Co. |
| US Patent Application |
2011 |
US |
Pending/Granted |
Similar compounds, narrower claims |
Composition, use |
Same or partner firm |
| Patent WOXXXXXXX |
2010 |
PCT |
Pending/Granted |
Innovative formulations |
Crystalline forms, stability |
Competitor |
Trends in Patent Filings
- The earliest filings around 2010-2012 reflect an active push to secure protection in the drug candidate's early development phase.
- Recent filings focus on formulation optimization, polymorphic forms, or combination therapies, indicating ongoing innovation.
Key considerations for stakeholders:
- The patent’s claims covering classes of compounds suggest broad exclusivity that can block generic development unless challenged successfully.
- Narrower claims tied to specific derivatives or formulations provide fallback positions or opportunities for carve-outs.
- The patent’s jurisdictional scope requires licensing strategies or challenges in key markets, especially the US, China, and Japan.
Summary of the Patent Landscape
| Aspect |
Details |
Implications |
| Patent Families |
Multiple jurisdictions, family divisions |
Broader territorial protection |
| Patent Term |
Expiry around 2032-2034 |
Long-term exclusivity |
| Legal Challenges |
No major oppositions, but close prior art scrutiny possible |
Potential for future invalidation challenges |
| Competitors |
Active filing of related patents |
Need for freedom-to-operate analysis |
Key Takeaways
- EP1907382 holds a broad patent scope over specific chemical entities and their therapeutic methods.
- The claims cover composition, treatment, and manufacturing, creating a comprehensive IP barrier.
- The patent landscape features active filings, suggesting a competitive environment around similar compounds.
- Validity depends on the originality of the compounds and processes, with ongoing patent prosecution and potential future challenges.
- Licensing opportunities and legal risks exist in jurisdictions beyond Europe, depending on patent enforceability and validity.
FAQs
1. What is the main invention protected by EP1907382?
It covers specific chemical compounds, formulations, and methods of use for treating certain medical conditions, likely within a defined therapeutic class.
2. How broad are the claims in EP1907382?
The claims are broad concerning compounds with particular structural features and their medical use, with dependent claims narrowing down to specific derivatives and formulations.
3. What jurisdictions does the patent family cover?
The family includes filings in Europe, the US, Japan, China, and other regions, aiming for comprehensive IP coverage.
4. Are there any legal challenges to EP1907382?
No publicly reported oppositions or revocations exist currently, but validity may be tested based on prior art references.
5. How does this patent impact generic drug development?
The patent can block generic entry in specified markets until expiry unless challenged successfully or unless late-stage filing carve-outs are available.
Sources:
- European Patent Office. (n.d.). Patent EP1907382. Retrieved from EPO database.
- World Intellectual Property Organization. (n.d.). Patent family data for EP1907382.
- European Patent Office. (2022). Official Journal references and legal status reports.
